







































CDH1 = E-cadherin gene; DCIS = ductal carcinoma in situ; LCIS = lobular carcinoma in situ; LOH = loss of heterozygosity.
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Introduction
The homotypic cellular adhesion molecule E-cadherin is
one of the most vital components in the cell. It is impli-
cated as a key player in different cellular processes includ-
ing development, morphology, polarity, migration and
tissue integrity [1]. E-cadherin is a glycoprotein with an
extracellular domain that interacts with E-cadherin mole-
cules on adjacent cells, thereby establishing adhesion
between epithelial cells. The intracellular domain is associ-
ated with a complex of proteins called catenins, which
anchor E-cadherin to the actin cytoskeleton.
In various carcinomas, plasma membrane associated
E-cadherin protein expression is decreased or even
absent. There is transcriptional regulation of this molecule
for which a number of factors have been implicated,
including promotor hypermethylation [2,3], and several
proteins that regulate E-cadherin transcription, especially
Snail-1 [4], SIP-1 [5] and integrin-linked kinase [6]. Muta-
tional inactivation of the E-cadherin gene CDH1 has been
reported in diffuse gastric cancer and lobular breast
cancer [7]. Both these tumour types have a characteristic
diffuse growth pattern with loss of cellular coherence that
is in accordance with the adhesion function of the absent
E-cadherin protein.
The wild type CDH1 allele is missing in most lobular
tumours due to loss of heterozygosity (LOH) at chromo-
some 16q [8], thereby presenting a classical example of
Knudson’s two-hit hypothesis on the inactivation of tumour
suppressor genes. The more frequent ductal breast carci-
nomas also show frequent LOH at 16q; however, these
tumours do not have mutational inactivation of the retained
CDH1 allele [9]. Given the importance and widespread
involvement of E-cadherin in tumorigenic processes, it is
tempting to assume that a decrease in E-cadherin activity
in ductal carcinomas is selected for and is reflected by
LOH at 16q. Indeed, haploinsufficiency has now been
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acknowledged as a true mechanism for tumour suppres-
sor gene inactivation [10]. However, other genes at 16q
could be targets of LOH in ductal tumours, justifying
ongoing gene hunts.
LOH at 16q in ductal and lobular breast
cancer
LOH at 16q is the second most frequent somatic genetic
event in breast cancer. This event occurs in about 50% of
all ductal carcinomas [11] and is slightly more frequent in
lobular breast cancer [8]. To confirm E-cadherin as the
target of LOH in ductal carcinoma, it is important to distin-
guish physical loss and mitotic recombination [12,13].
Only the first LOH event could theoretically lead to haplo-
insufficiency of CDH1. This seems unlikely, however,
since there are so many complex mechanisms for regula-
tion of CDH1 transcription that are often part of feedback
loops [14]. Furthermore, our observations (unpublished
data) on LOH at 16q in breast cancer indicate that both
mechanisms for LOH are operative.
E-cadherin protein expression in ductal and
lobular breast cancer
The complete absence of E-cadherin plasma membrane
associated protein expression as detected by immuno-
histochemistry is so unambiguous that pathologists use
this immunostaining to confirm their diagnosis of lobular
breast cancer. We have stained a series of 86 breast
carcinomas with known E-cadherin mutation status for
E-cadherin protein expression [15]. Complete loss of
protein was found in all lobular tumours with mutational
inactivation of E-cadherin (n = 21). In addition, we were
unable to detect E-cadherin in 11 lobular tumours in which
no mutation had been identified. This is probably due to
insensitivity of the mutation detection method or because
other mechanisms of inactivation (e.g. methylation) were
active. Remarkably, six cases of lobular breast cancer
without a detectable E-cadherin mutation were positive for
E-cadherin immunostaining. Of the 48 ductal breast
cancers tested, 37% showed a decrease in but never a
complete absence of E-cadherin protein expression. If
E-cadherin was the target of LOH at 16q in ductal breast
cancer, one would expect a strong association between
LOH at 16q and decreased E-cadherin expression.
However, the percentage of LOH at 16q in tumours with
and without E-cadherin decrease was equal. It therefore
seems unlikely that LOH at 16q is associated with a
decrease in E-cadherin expression in ductal breast cancer.
Also, in ductal carcinoma in situ (DCIS), there is no asso-
ciation between LOH at 16q and a decrease in E-cadherin
expression. This can be derived from our combined data
on LOH and E-cadherin immunohistochemistry, which was
available for 62 cases of pure DCIS [16,17].
The adhesion function of E-cadherin is strongly indicative
of a function in invasion suppression and this has indeed
been shown in vitro [18] and in mouse models [19]. Inves-
tigation in primary tumours showed that this function trans-
lates well into metastatic potential [20]. There is no
significant correlation between LOH at 16q in breast
cancer and metastatic potential [11], however, which
further contradicts an association between E-cadherin and
LOH at 16q.
A breast cancer progression model
The invasion suppressor function of E-cadherin is very
obvious, but not in concordance with our earlier finding
[16] that mutational inactivation of both CDH1 alleles
through LOH and truncating mutations occurs in the prein-
vasive stage in lobular carcinoma in situ (LCIS), a tumour
stage that involves proliferation but not dissemination. We
showed that the same mutation and LOH at 16q was
present in the invasive tumour and the adjacent LCIS [16].
E-cadherin may thus play a role in invasive capacity, but
more data suggest other signalling mechanisms may be
involved in earlier tumorigenic processes, especially cellu-
lar proliferation. Indeed, E-cadherin is implicated in several
signalling pathways: Wnt, Rho/Rac and p27Kip1, which are
involved in transcriptional activation, actin cytoskeleton
reorganisation and contact inhibition, respectively [14].
LOH at 16q also occurs in the preinvasive stage, predomi-
nantly in grade I DCIS and in LCIS [17,21]. These obser-
vations and data in the literature led to a progression
model of breast cancer (Fig. 1) based on early genetic
alterations [17]. A similar multistep model for breast car-
cinogenesis has been proposed by Lakhani [22]. The
model by Vos et al. [17] is less well defined than the
Vogelstein model for colorectal cancer, because the latter
is based on specific tumour stages and gene mutations.
Similar stages are not defined for breast cancer and most
of the genes involved are not yet identified. However,
somatic genetic alterations in DCIS, LCIS and invasive
carcinoma indicate that breast cancer progression is also
based on the accumulation of genetic alterations. LOH at
16q in grade I DCIS and LCIS led us to suggest that
grade I DCIS may be a precursor for LCIS. Loss of E-cad-
herin further determines the histological fate of the tumour.
Loss of chromosome 16q in grade I ductal and lobular
breast cancer also lead Roylance et al. to speculate that
these apparently morphological different tumours have a
common molecular origin [23]. The observation of mixed
populations of tumour cells, LCIS adjacent to DCIS, infil-
trating lobular carcinoma and infiltrating ductal carcinoma
(Fig. 2) supports this model, as well as investigations by
Buerger et al. [24] on comparative genomic hybridisation
of different tumour populations within the same lesion.
E-cadherin germline mutations and lack of
LOH in gastric cancer
The identification of somatic E-cadherin mutations in







































the report on two Maori families with diffuse gastric
cancer attributed to germline transmission of truncating
mutations in CDH1 [25]. Although lobular breast cancer
was expected, none was registered in these Maori fami-
lies or in others reported on later [26]. Examination of
CDH1 in 65 patients with LCIS revealed no germline
mutations [27]. Loss of one CDH1  allele apparently
gives an increased risk only for gastric cancer, both
hereditary and sporadic.
Remarkably, at the level of LOH, there is also a substan-
tial difference between breast and gastric tumours. In
diffuse gastric tumours, the wild type CDH1 allele is inac-
tivated not by LOH at 16q, but by promotor methylation
[28]. This marked difference in general genetic mecha-
nism may reflect a difference in the role of the tumour
suppressor gene. Whereas the loss of E-cadherin is a
rate-limiting factor in gastric cancer, in breast cancer it
probably plays a role in a later stage and it determines the
histological subtype.
Conclusions
LOH at chromosome arm 16q in breast cancer is a fre-
quent event, occurring in at least 50% of breast cancer
cases. In lobular breast cancer, a histological minority
comprising 5–10% of all breast cancers, the E-cadherin
gene is the target of this somatic genetic event. In ductal
breast cancer it is unlikely that CDH1 is the target tumour
suppressor gene, and other genes therefore remain to be
identified. Classical LOH mapping efforts have not been
successful in the identification of these target genes at
chromosome 16, or other genes in other tumour types,
and we therefore need to apply different high-throughput
screening methods to identify these remaining genes.
The E-cadherin gene has many different functions, even in
carcinogenesis, given its involvement in early lesions and
metastasis, hereditary and sporadic tumours, and numer-
ous different tumour types. To elucidate whether this
remarkable diversity indicates true separate activities or is
a reflection of this protein’s central role in cellular
Available online http://breast-cancer-research.com/content/4/1/005
Figure 1
Model of breast cancer progression. Grade II tumours are omitted for simplification. Two possible pathways may result in lobular carcinoma: 
1, direct; or 2, via well-differentiated ductal carcinoma in situ (CIS). IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; LOH, loss
of heterozygosity.
Figure 2
E-cadherin staining of mixed populations of (a) ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), and (b) infiltrating ductal
carcinoma (IDC) and infiltrating lobular carcinoma (ILC). The E-cadherin staining was performed with antibody HECD-1 and distinguishes ductal
from lobular tumour cells. Courtesy of Dr CBJ Vos.
(a)                                                                        (b)processes will be a challenging task for cellular biologists,
geneticists and oncology researchers together.
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